<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04925206</url>
  </required_header>
  <id_info>
    <org_study_id>EDG-001</org_study_id>
    <nct_id>NCT04925206</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study Evaluating ET-01 in Subjects With Transfusion Dependent β-Thalassaemia</brief_title>
  <acronym>ET-01</acronym>
  <official_title>A Multicenter, Open Label Phase 1 Study to Evaluate the Safety and Efficacy of a Single Dose of Autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (hHSPCs) in Subjects With Transfusion Dependent β-Thalassaemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EdiGene (GuangZhou) Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EdiGene (GuangZhou) Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-arm, open label, multi-center, single-dose phase 1 study in subjects with&#xD;
      transfusion dependent β-thalassaemia. The study will evaluate the safety and efficacy of&#xD;
      autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (hHSPCs)&#xD;
      using ET-01.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 17, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency and severity of collected AEs &amp; SAEs</measure>
    <time_frame>Within 24 months after ET-01 infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>From signing of informed consent up to 24 months post-ET-01 infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of transplant-related mortality</measure>
    <time_frame>From baseline (pre-transfusion) up to 12 months post-ET-01 infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total lymphocyte count</measure>
    <time_frame>Within 24 months after ET-01 infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects with abnormal proliferation of blood cells</measure>
    <time_frame>Within 24 months after ET-01 infusion</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Transfusion Dependent Beta-Thalassaemia</condition>
  <arm_group>
    <arm_group_label>ET-01</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ET-01</intervention_name>
    <description>Recruited participants will receive ET-01 IV infusion following myeloablative conditioning with busulfan.</description>
    <arm_group_label>ET-01</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Subjects and/or legal representative fully understand and voluntarily sign informed&#xD;
             consent forms.&#xD;
&#xD;
          -  Diagnosis of transfusion dependent β-thalassemia (β-TDT) as defined by protocol.&#xD;
&#xD;
          -  Be not appropriate to receive conventional allogeneic hematopoietic stem cell&#xD;
             transplantation.&#xD;
&#xD;
          -  Lansky/Karnofsky score ≥ 70%.&#xD;
&#xD;
          -  Eligible for hematopoietic stem cell transplantation and conditioning with busulfan as&#xD;
             per investigator's judgement.&#xD;
&#xD;
        Other protocol defined inclusion criteria may apply.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with associated α-thalassemia.&#xD;
&#xD;
          -  Subjects with any clinically significant acute or uncontrolled infections.&#xD;
&#xD;
          -  History of uncontrolled epilepsy or other mental disorders.&#xD;
&#xD;
          -  Previous treatment with allogeneic bone marrow transplantation or gene therapy.&#xD;
&#xD;
        Other protocol defined exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ge Zhang, MD</last_name>
    <phone>(86)1080733899</phone>
    <phone_ext>8166</phone_ext>
    <email>peter@edigene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nanfang Hospital of Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Guangzhou Women and Children's Medical Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510623</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shenzhen Children's Hospital</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518035</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institute of Hematology &amp; Blood Diseases Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 4, 2021</study_first_submitted>
  <study_first_submitted_qc>June 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2021</study_first_posted>
  <last_update_submitted>August 26, 2021</last_update_submitted>
  <last_update_submitted_qc>August 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Beta-Thalassaemia</keyword>
  <keyword>CRISPR-Cas9</keyword>
  <keyword>Human Hematopoietic Stem and Progenitor Cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>beta-Thalassemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

